Prevalence and predictors of survival among patients with prostate cancer attending Nyeri County and referral hospital, Kenya: a review of records 2017-2022

Moses M. Gitonga; Florence W. Mbuthia; Beth Mbuthia

doi:10.18203/2394-6040.ijcmph20233428

Authors

Moses M. Gitonga Department of Community Health, Dedan Kimathi University of Technology, Kenya
Florence W. Mbuthia Department of Reproductive Health, Dedan Kimathi University of Technology, Kenya
Beth Mbuthia Department of Oncology, Nyeri County and Referral Hospital, Nyeri, Kenya

DOI:

https://doi.org/10.18203/2394-6040.ijcmph20233428

Keywords:

Prostate cancer, Comorbidities, Treatment modalities, Predictors, Survival outcomes, Prevalence

Abstract

Background: Prostate cancer is a significant health concern globally. The incidence rate of prostate cancer (PCa) has continued to rise in Kenya. This study aimed to investigate the prevalence of prostate cancer in patients attending Nyeri County and referral hospital in Kenya, identify predictors of survival, and assess the impact of treatment modalities on survival outcomes.

Methods: A retrospective observational design was employed, analyzing data from 252 patient records documented between 2017 and 2022. Demographic characteristics, clinical features, treatment modalities, and survival outcomes were extracted and analyzed.

Results: The prevalence of prostate cancer among the study population was found to be 10.84%. The majority of patients diagnosed with prostate cancer were aged 70 years or older, with none below 40 years. Most patients were residents of Nyeri County, and some came from neighboring counties in central Kenya. The overall survival rate for prostate cancer patients was 64.29%, indicating that 35.71% of patients died during the study period. Advanced age, comorbidities, and late-stage diagnosis were associated with lower survival rates. Multivariate analysis revealed that prostate cancer cases with hypertension were 2.91 times more likely to die compared to those without comorbidities (p=0.01, CI: 1.285051-6.597691).

Conclusions: The study highlights a significant prevalence of prostate cancer in the region and emphasizes the need for enhanced management strategies. Early detection programs, tailored treatment approaches considering comorbidities, and improved access to healthcare services are recommended to enhance survival rates and overall management of prostate cancer in this population.

Metrics

Metrics Loading ...

References

Pernar CH, Ebot EM, Wilson KM, Mucci LA. The epidemiology of prostate cancer. Cold Spring Harbor Perspect Med. 2018:a030361.

Teoh JY, Hirai HW, Ho JM, Chan FC, Tsoi KK, Ng CF. Global incidence of prostate cancer in developing and developed countries with changing age structures. PloS One. 2019;14(10):e0221775.

Torre LA, Bray F, Siegel RL, Ferlay J, Lortet‐Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87-108.

Withrow D, Pilleron S, Nikita N, Ferlay J, Sharma S, Nicholson B, et al. Current and projected number of years of life lost due to prostate cancer: A global study. Prostate. 2022;82(11):1088-97.

Lin L, Li Z, Yan L, Liu Y, Yang H, Li H. Global, regional, and national cancer incidence and death for 29 cancer groups in 2019 and trends analysis of the global cancer burden, 1990-2019. J Hematol Oncol. 2021;14(1):1-24.

Kaninjing E, Lopez I, Nguyen J, Odedina F, Young ME. Prostate cancer screening perception, beliefs, and practices among men in Bamenda, Cameroon. Am J Men's Health. 2018;12(5):1463-72.

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-49.

Makau-Barasa LK, Manirakiza A, Carvalho AL, Rebbeck TR. Prostate cancer screening, diagnostic, treatment procedures and costs in Sub-Saharan Africa: a situational analysis. Cancer Control. 2022;29:10732748221084932.

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424.

Seraphin TP, Joko-Fru WY, Kamaté B, Chokunonga E, Wabinga H, Somdyala NI, et al. Rising prostate cancer incidence in sub-Saharan Africa: a trend analysis of data from the African cancer registry network. Cancer Epidemiol Biomark Prevent. 2021;30(1):158-65.

Parkin DM, Sitas F, Chirenje M, Stein L, Abratt R, Wabinga H. Part I: Cancer in Indigenous Africans-burden, distribution, and trends. Lancet Oncol. 2008;9(7):683-92.

Maiyoh GK, VC Tuei. Rising cancer incidence and role of the evolving diet in Kenya. Nutr Cancer. 2019;71(4):531-46.

Gaitho J. Modelling survival among patients with prostate Cancer in Kenya. University of Nairobi. 2021.

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424.

Zhang Z, Zhanghuang C, Wang J, Tian X, Wu X, Li M, et al. Development and validation of nomograms to predict cancer-specific survival and overall survival in elderly patients with prostate cancer: a population-based study. Front Oncol. 2022;12:918780.

Hamada A, Sato Y, Shinojima T, Shiraishi T, Oya M, Fujimoto K, et al. Impact of age on the overall survival of patients with prostate cancer: a large cohort analysis in the Japanese population. J Cancer Res Clin Oncol. 2021;147(1):251-9.

Zhang G, Liu X, Wang J, Li J, Wang B, Ma L, et al. Marital status and overall survival in patients with prostate cancer: a population-based, propensity score-matched study. Front Oncol. 2021;11.

Wu Y, Xie C, Wu J, Yu H, Wang Y, Xu J. Impact of demographic factors on survival of patients with prostate cancer: a population-based study using the SEER database. Cancer Manage Res. 2021;13:9793-803.

Di Pietro G, Chornokur G, Kumar NB, Davis C, Park JY. Racial differences in the diagnosis and treatment of prostate cancer. Int Neurourol J. 2016;20(Suppl 2):S112.

Wanjiru E, Gitau G, Njoroge M, Gachuki T, Mbugua J, Muthumbi E, et al. Prostate cancer survival rates and predictors among patients in central Kenya. J Cancer Res Clin Oncol. 2022;148(3):729-38.

Wallis CJD, Herschorn S, Saskin R, Suissa S, Klotz L. Hypertension and increased mortality among patients with prostate cancer. Eur Urol. 2021;80(3):342-51.

Zhang X, Xu X, Huang W, Chen C, Chen H, Wu Q, et al. Comorbidities and survival in prostate cancer patients: a systematic review and meta-analysis. Eur J Cancer Care. 2021;30(1).

Ning Y, Su J, Shi W, Zhang X, Kong C, Huang Y, et al Hypertension and prostate cancer mortality: a systematic review and meta-analysis. Eur Urol Focus. 2021;S2405-4569(21):00262-9.